Ceftriaxone compared with cefotaxime for serious bacterial infections

Craig R. Smith, Brent G. Petty, Craig W. Hendrix, Walter N. Kernan, Patty L. Garver, Kevin Fox, Andrew Beamer, Kathy Carbone, Michael Threlkeld, Paul S. Lietman

Research output: Contribution to journalArticlepeer-review

Abstract

Ceftriaxone was compared with cefotaxime for the treatment of serious bacterial infections in a prospective, randomized, double-blind clinical trial. The dose of ceftriaxone was 2 g once a day, and the dose of cefotaxime was 2 g every 4 h. Metronidazole was added if anaerobic infection was suspected. Explicit criteria were used to define infections, clinical response, and adverse effects. Ceftriaxone wasgiven to 88patients and cefotaxime to 83. The two treatment groups did not differ in types of infection, infecting organisms, and severity of underlying disease. The response rate was 81070 (71/88) for ceftriaxone and 80% (66/83) for cefotaxime. The power of the study to detect a 15% difference in response rate at P<.1was 90070. The frequency of diarrhea, thrombophlebitis, prothrombin time, prolongation, colonization, and superinfection did not differ between treatment groups. Ceftriaxone 2 g once a day was as safe and effective as cefotaxime 2 g every 4 h for suspected serious bacterial infections.

Original languageEnglish (US)
Pages (from-to)442-447
Number of pages6
JournalJournal of Infectious Diseases
Volume160
Issue number3
DOIs
StatePublished - Sep 1989

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Ceftriaxone compared with cefotaxime for serious bacterial infections'. Together they form a unique fingerprint.

Cite this